엔비팜

NB Pharm is a South Korean biopharmaceutical company focused on the development of long-acting injectable (LAI) drugs using proprietary drug delivery system (DDS) technologies. The company specializes in sustained-release microsphere formulations that allow for controlled drug release over weeks or months, significantly improving patient adherence in chronic disease management. Their research and development efforts primarily target the central nervous system (CNS), oncology, and metabolic diseases. Key programs in their pipeline include long-acting versions of treatments for schizophrenia, Alzheimer's disease, and prostate cancer. NB Pharm aims to provide value-added medicines by optimizing existing therapeutic agents through innovative formulation science.